荟萃分析
医学
内科学
随机对照试验
安慰剂
塞来昔布
科克伦图书馆
评定量表
优势比
汉密尔顿抑郁量表
严格标准化平均差
重性抑郁障碍
萧条(经济学)
心情
精神科
心理学
替代医学
经济
病理
宏观经济学
发展心理学
作者
Farhad Farıdhosseını,Ramin Sadeghi,Layla Farid,Meysam Pourgholami
摘要
Objective The aim of this research was to perform a systematic review to identify all randomized controlled trials (RCTs) evaluating the efficacy and safety of add‐on celecoxib for treatment of depressive mood episodes. Methods Four electronic databases were systematically searched from their inception to 8 August 2013: PubMed, Cochrane Library (Cochrane Central Register of Controlled Trials), Scopus, and PsychINFO. Pooled difference in means of Hamilton Depression Rating Scale score, pooled odds ratio (OR) of treatment response, and pooled OR of remission were calculated as the main effect size. A random‐effects model was used to pool the data across studies. Results Five RCTs (four unipolar depression studies and one bipolar depression study) were included in the systematic review for qualitative data synthesis. Moreover, quantitative results of four RCTs (unipolar depression studies) were meta‐analyzed. The add‐on celecoxib group had a statistically significant decrease in means of the Hamilton Depression Rating Scale score at week 4 (pooled difference in means = 3.3, 95%CI [1.2–5.3], p = 0.002) and week 6 (pooled difference in means = 3.43, 95%CI [1.9–4.9], p < 0.0001). The add‐on celecoxib group also showed higher response (pooled OR = 6.6, 95%CI [2.5–17], p < 0.0001) and remission rates (pooled OR = 6.6, 95%CI [2.7–15.9], p < 0.0001) compared with the placebo group. Conclusions Celecoxib can be considered as an effective add‐on treatment for unipolar depressive patients. Making conclusion regarding the efficacy and safety for longer duration warrants further studies with a larger sample size and longer follow‐up duration. Copyright © 2014 John Wiley & Sons, Ltd.
科研通智能强力驱动
Strongly Powered by AbleSci AI